Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Receivables - Net (2023 - 2025)

Historic Receivables - Net for Iovance Biotherapeutics (IOVA) over the last 3 years, with Q3 2025 value amounting to $66.8 million.

  • Iovance Biotherapeutics' Receivables - Net rose 1971.2% to $66.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.8 million, marking a year-over-year increase of 1971.2%. This contributed to the annual value of $69.3 million for FY2024, which is 4582052.98% up from last year.
  • According to the latest figures from Q3 2025, Iovance Biotherapeutics' Receivables - Net is $66.8 million, which was up 1971.2% from $59.9 million recorded in Q2 2025.
  • Over the past 5 years, Iovance Biotherapeutics' Receivables - Net peaked at $70.9 million during Q1 2025, and registered a low of $33000.0 during Q2 2023.
  • Moreover, its 3-year median value for Receivables - Net was $55.8 million (2024), whereas its average is $39.4 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first surged by 9566969.7% in 2024, then surged by 1971.2% in 2025.
  • Iovance Biotherapeutics' Receivables - Net (Quarter) stood at $151000.0 in 2023, then soared by 45820.53% to $69.3 million in 2024, then fell by 3.72% to $66.8 million in 2025.
  • Its Receivables - Net was $66.8 million in Q3 2025, compared to $59.9 million in Q2 2025 and $70.9 million in Q1 2025.